Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Bronwyn Mixter
Jan. 25 — Sens. Ron Wyden (D-Ore.) and Charles Grassley (R-Iowa) Jan. 21 sent a letter to the health-care and patient community requesting responses to the policy questions in their report on the price of the hepatitis C drug Sovaldi.
The report, “The Price of Sovaldi and Its Impact on the U.S. Health Care System,” was released on Dec. 1, 2015 (13 PLIR 1698, 12/4/15). The report examined how Gilead Sciences Inc. developed, priced, marketed and sold Sovaldi and its follow-on drug Harvoni.
The report said the company pursued a marketing strategy and final wholesale price of Sovaldi—$1,000 per pill, or $84,000 for a single course of treatment—that it believed would maximize revenue. Building on that price, Harvoni was later introduced at $94,500 for a single course of treatment.
“We launched this investigation largely out of concern about the challenges that Gilead's pricing decisions posed for public payers and the negative impact that restricted access had on patients within those systems,” the letter said. “Now we seek to gather information from the public about how to address policy issues including the financial impact of high prices of breakthrough drugs, ensuring patient access, and improving marketplace transparency.”
Wyden is the ranking member of the Senate Finance Committee and Grassley is a senior committee member.
The senators asked for responses to the following questions:
The senators requests that all responses be sent in PDF format to Report_Feedback@finance.senate.gov by the close of business on March 4. All submissions will be considered part of the public record.
At the time the report was released, Foster City, Calif.-based Gilead said that it stands behind the pricing of its therapies because of the benefit they bring to patients and the significant value they represent to payers, providers and the entire health-care system by reducing the long-term costs associated with managing chronic hepatitis C virus.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Nancy Simmons at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)